IDH1 and central nervous system cancer: There were 10 patients who had histological diagnoses of glioblastoma WHO grade IV, 1 with glioma WHO grade III, 3 with R132H IDH1-mutated WHO grade II diffuse astrocytoma, and 2 with a diffuse astrocytoma that was IDH1-negative WHO grade II.